Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
New study sheds light on how Epstein-Barr virus may contribute to multiple sclerosis
medicalxpress - Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the central nervous system. For years, Epstein-Barr virus (EBV) has been strongly linked to MS, as nearly every person diagnosed with the condition shows evidence of past EBV infection.…
AI Summary: Researchers report that immune responses to Epstein‑Barr virus are implicated in multiple sclerosis, with EBV‑reactive CD4+ T cells enriched in people with MS. The work provides mechanistic evidence connecting prior infection to neuroinflammation and suggests antiviral or immune‑directed strategies might be viable prevention or treatment avenues — assuming we like attacking tiny viral culprits.
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Genetic study redefines a form of excessive sweating as a treatable neurological condition
medicalxpress - An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered a major genetic cause of hyperhidrosis (chronic and excessive sweating). The study, published in Science Advances, provides strong evidence that a genetica…
AI Summary: New research identifies a genetic basis and a tiny electrically gated ion channel in nerve cells as drivers of a form of excessive sweating, recasting it as a neurological condition rather than a benign nuisance. Findings point to potential targeted therapies that address the underlying neural mechanism rather than symptom management alone.